covid-19 treatment
EMA begin review of GSK & Vir COVID-19 treatment
May 10, 2021Sales and Marketing COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir
The EMA has begun a rolling review of GSK and Vir’s sotrovimab treatment for COVID-19, which will continue until there …
Celltrion’s COVID-19 treatment shows promise against South African variant
April 30, 2021Medical Communications COVID-19, celltrion, covid 19 news, covid-19 news, covid-19 treatment, pharma, pharma news
Celltrion’s regdanvimab treatment for COVID-19 has shown itself to be effective against the South African variant of the virus, according …
Jubilant’s oral remdesivir formulation shows positive results in human trial
April 22, 2021COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir
Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …
Adagio raises $336 million to advance COVID-19 antibody
April 20, 2021Manufacturing and Production Adagio, COVID-19, Financing, covid-19 treatment, pharma, pharma news
Adagio Therapeutics has financed $336 million to support the rapid advancement of their novel ADG20 antibody for the treatment and …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
April 19, 2021Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …
Merck cease development of $425 million COVID-19 treatment
April 16, 2021Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news
Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.
EMA to begin review of GSK and Vir’s COVID-19 treatment
April 16, 2021Medical Communications COVID-19, EMA, GSK, covid-19 treatment, pharma, pharma news, vir
The EMA have begun a review of GSK and Vir Biotechnology’s investigational COVID-19 antibody (VIR-7831) for patients at high risk …
AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19
April 13, 2021Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news
AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …
Regeneron’s drug cocktail shown to prevent symptomatic COVID-19
April 13, 2021Manufacturing and Production COVID-19, REGEN-COV, Regeneron, covid-19 treatment, pharma, pharma news
Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …
GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial
March 29, 2021Sales and Marketing COVID-19, GSK, Phase III trial, covid-19 treatment, vir
GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the …
Merck and UCLA find new COVID-19 treatment candidate
March 25, 2021COVID-19, Merck, berzosertib, covid-19 treatment, ucla
Merck (MSD in the UK), the UCLA, and other universities from the US and Germany have uncovered a compound that …
Roche’s drug cocktail reduces hospitalisation due to COVID-19 in Phase III trial
March 24, 2021Research and Development COVID-19, Roche, covid-19 treatment
Roche’s antibody drug combination of casirivimab and imdevimab has shown to reduce hospitalisation or death by 70% in non-hospitalised patients …
Kintor’s COVID-19 treatment reduces mortality by 92%
March 12, 2021Medical Communications Brazil, Brazil variant, COVID-19, Kintor, covid-19 treatment
Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by 92%, in a clinical trial …
Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial
March 11, 2021COVID-19, Eli Lilly, covid-19 treatment
Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …
GSK’s Phase II otilimab study on COVID-19 patients promising for over-70s
February 26, 2021Medical Communications COVID-19, GSK, coronavirus, covid-19 treatment, otilimab
GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has shown promising results in older …
